Form EFFECT Aspire Biopharma Holding
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 14, 2026 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
- Epsilon Energy Ltd. Schedules Second Quarter 2026 Earnings Release and Conference Call
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
